The U.S. Food and Drug Administration approved Edwards Lifesciences' Autus pulmonary valve, a device that is surgically implanted at a size of approximately 13 millimeters and can later be expanded to 22 millimeters using a catheter-and-balloon procedure to accommodate the child's growth. The valve is intended for children who need pulmonary valve replacement, particularly those with congenital heart disease.
The importance of the design lies in its potential to reduce the number of open-heart surgeries a child needs during the stages of growth. FDA officials said the valve could reduce the need to return repeatedly to the operating room, an ongoing treatment challenge in children: early intervention may require additional surgeries as the heart grows, while waiting too long may harm the child.
A Different Material from Traditional Valves
The FDA said Autus is the first approved valve to use a synthetic polymer material in its leaflets instead of animal tissue in any medical application. The agency said animal tissue used in traditional valves tends to stiffen and deteriorate more quickly in children, which may limit its functional lifespan.
Acting FDA Commissioner Kyle Diamantas described the approval as a turning point for patients whose surgical options had been limited. Michelle Tarver, director of the agency's Center for Devices and Radiological Health, also said that expandability could make the timing of valve replacement less tied to repeated surgeries.
What Did the Study Show?
The approval was based on a pivotal study involving 62 children at 12 U.S. sites, and Edwards said the study met its two primary safety and effectiveness endpoints. All participants underwent a successful procedure. After six months, the first 60 patients showed blood flow through the right side of the heart within acceptable limits, and regurgitation through the valve did not exceed the level of mild leakage.
A fracture in the valve frame was recorded in three patients, and reduced movement of one leaflet occurred in two patients, but the FDA said none of these events caused symptoms. The valve's performance also began to decline in two patients because they had grown and outgrown its size, and both valves were successfully expanded without invasive surgery.
What Changes in Practice?
The approval provides a treatment option that can adapt to the child's growth, but it does not eliminate the need for long-term follow-up. First-year data showed that the synthetic leaflets maintained good performance, but participants will continue to be followed for 10 years, an important period for assessing durability, expansion rates, and late complications.
Edwards acquired the valve technology in February as part of a $128.9 million deal to purchase Autus Valve Technologies, with milestone-related payments of up to $132.5 million. The company had previously paid $11.5 million for the acquisition option. The device had previously received breakthrough device designation from the FDA, and it also became the first pediatric approval to emerge from the agency's full product life-cycle advisory program.